Mesoblast Limited - Product Pipeline Review - 2012

Summary

“Mesoblast Limited - Product Pipeline Review - 2012” provides data on the Mesoblast Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Mesoblast Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Mesoblast Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Mesoblast Limited - Brief Mesoblast Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Mesoblast Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Mesoblast Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Mesoblast Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Mesoblast Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Mesoblast Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Mesoblast Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Mesoblast Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Mesoblast Limited and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Mesoblast Limited Snapshot 6
Mesoblast Limited Overview 6
Key Information 6
Key Facts 6
Mesoblast Limited – Research and Development Overview 7
Key Therapeutic Areas 7
Mesoblast Limited – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products –  Monotherapy 11
Mesoblast Limited – Pipeline Products Glance 12
Mesoblast Limited – Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Mesoblast Limited Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Mesoblast Limited – Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Mesoblast Limited – Drug Profiles 15
Adult-derived Mesenchymal Precursor Cells for Diabetes 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
bone marrow-derived allogeneic mesenchymal precursor cells 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Drug Targeting Plasminogen Activator Inhibitor Type 1 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Drug Targeting Stromal-Derived Factor 1 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NeoFuse 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RepliCart 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
revascor 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Stem Cells For Chronic Back Pain 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Stem Cells For Diabetic Macular Edema 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Stem Cells For Macular Degeneration 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Mesoblast Limited – Pipeline Analysis 29
Mesoblast Limited – Pipeline Products by Therapeutic Class 29
Mesoblast Limited – Pipeline Products by Route of Administration 30
Mesoblast Limited – Pipeline Products By Mechanism of Action 31
Mesoblast Limited –  Recent Pipeline Updates 32
Mesoblast Limited – Company Statement 35
Mesoblast Limited – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Mesoblast Limited, Recent Developments 38
Mesoblast Limited- Press Release 38
Jul 24, 2012: Mesoblast Announces Positive Preclinical Results Of Intravenously Injected Adult Stem Cells For Treatment Of Rheumatoid Arthritis 38
Apr 17, 2012: Mesoblast Announces Intervertebral Disc Repair Phase II Trial Update 39
Jan 31, 2012: Mesoblast Receives FDA Clearance For Phase II Clinical Trial Of Stem Cell Therapy In Type 2 Diabetes 40
Nov 18, 2009: Heart failure clinical trial results highlighted at American Heart Association annual meeting 40
Aug 05, 2009: Proprietary Technology in World-first Allogeneic Stem Cell Trial for Treatment of End-stage Heart Failure in Patients Supported by Mechanical Heart Assist Devices 41
May 14, 2009: Heart Muscle Function Improved Significantly After Single, Lowest-dose Injection of “off-the-shelf” Stem Cells in Patients with Heart Failure 42
Feb 25, 2009: First Group of Heart Failure Patients Treated With “off-the-shelf” Adult Stem Cells Successfully Pass Key Safety Milestone 43
Jan 20, 2009: 43
Financial Deals Landscape 45
Mesoblast Limited, Deals Summary 45
Mesoblast Limited, Pharmaceuticals & Healthcare, Deal Details 46
Partnerships 46
Parkway Group Healthcare Enters Into Co-Marketing Agreement With Mesoblast 46
Angioblast Systems Enters Into A Co-Development Agreement With Abbott India 47
Licensing Agreements 48
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine 48
Equity Offering 50
Mesoblast Completes Private Placement Of $33 Million 50
Angioblast Systems Completes Private Placement Of Common Stock For $8 Million 52
Mesoblast Completes Private Placement Of $7.51 Million 53
Mesoblast Completes Private Placement For $12 Million 54
Mesoblast Completes Public Offering Of $1.6 Million 55
Mesoblast Completes Private Placement Of $11 Million 57
Acquisition 59
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 59
Mesoblast Completes Acquisition Of Additional Stake In Angioblast Systems 61
Mesoblast Acquires Additional Stake In Angioblast 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Mesoblast Limited, Key Information 6
Mesoblast Limited, Key Facts 6
Mesoblast Limited – Pipeline by Indication, 2012 8
Mesoblast Limited – Pipeline by Stage of Development, 2012 10
Mesoblast Limited – Monotherapy Products in Pipeline, 2012 11
Mesoblast Limited – Phase III, 2012 12
Mesoblast Limited – Phase II, 2012 13
Mesoblast Limited – Pre-Clinical, 2012 14
Mesoblast Limited – Pipeline By Therapeutic Class, 2012 29
Mesoblast Limited – Pipeline By Route of Administration, 2012 30
Mesoblast Limited – Pipeline Products By Mechanism of Action, 2012 31
Mesoblast Limited – Recent Pipeline Updates, 2012 32
Mesoblast Limited, Other Locations 37
Mesoblast Limited, Subsidiaries 37
Mesoblast Limited, Deals Summary 45
Parkway Group Healthcare Enters Into Co-Marketing Agreement With Mesoblast 46
Angioblast Systems Enters Into A Co-Development Agreement With Abbott India 47
Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine 48
Mesoblast Completes Private Placement Of $33 Million 50
Angioblast Systems Completes Private Placement Of Common Stock For $8 Million 52
Mesoblast Completes Private Placement Of $7.51 Million 53
Mesoblast Completes Private Placement For $12 Million 54
Mesoblast Completes Public Offering Of $1.6 Million 55
Mesoblast Completes Private Placement Of $11 Million 57
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 59
Mesoblast Completes Acquisition Of Additional Stake In Angioblast Systems 61
Mesoblast Acquires Additional Stake In Angioblast 63

List of Figures
Mesoblast Limited  – Pipeline by Indication, 2012 8
Mesoblast Limited  – Pipeline by Stage of Development, 2012 10
Mesoblast Limited – Monotherapy Products in Pipeline, 2012 11
Mesoblast Limited  – Pipeline By Therapeutic Class, 2012 29
Mesoblast Limited  – Pipeline By Route of Administration, 2012 30